Prevalence of thymine - Adenine dinucleotide repeat, IL28B and IFNL4 in Thai population and correlation with spontaneous clearance and treatment outcome of hepatitis C infection

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Thong, Vo Duy ^a,b   Wasitthankasem, Rujipat ^a   Tangkijvanich, Pisit ^a   Vongpunsawad, Sompong ^a   Poovorawan, Yong ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b UNIVERSITY OF MEDICINE AND PHARMACY AT HO CHI MINH CITY   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON LAMBDA 3; INTERFERON LAMBDA 4; INTERLEUKIN 28B; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; ADENINE; ANTIVIRUS AGENT; IFNL4 PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; THYMINE;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DINUCLEOTIDE REPEAT; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 6; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; THAI (PEOPLE); THYMINE ADENINE DINUCLEOTIDE REPEAT; VIRAL CLEARANCE; VIRUS LOAD; ALLELE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; THAILAND; TREATMENT OUTCOME; VIROLOGY;

HEPATITIS C VIRUS;

ADENINE; ADULT; ALLELES; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DINUCLEOTIDE REPEATS; FEMALE; GENE FREQUENCY; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; THAILAND; THYMINE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84929095185     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125400     Document Type: Article

References (27)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2011; 17 (2):107-15. PMID: 21091831.
2. Berg CL, Steffick DE, Edwards EB, Heimbach JK, Magee JC, Washburn WK, et al. Liver and intestine transplantation in the United States 1998-2007. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2009; 9(4 Pt 2):907-31. PMID: 19341415. doi: 10.1111/j.1600-6143.2009.02567.x
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England journal of medicine. 2002; 347 (13):975-82. PMID: 12324553.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286):958-65. PMID: 11583749.
5. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138(4):1338-45, 45 e1-7. PMID: 20060832. doi: 10.1053/j.gastro.2009.12.056
6. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262):399-401. PMID: 19684573. doi: 10.1038/nature08309
7. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nature genetics. 2009; 41(10):1105-9. PMID: 19749757. doi: 10.1038/ng.449
8. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature genetics. 2009; 41 (10):1100-4. Epub 2009/09/15. PMID: 19749758. doi: 10.1038/ng.447
9. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nature genetics. 2013; 45(2):164-71. PMID: 23291588. doi: 10.1038/ng.2521
10. Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M. Genetic variation of the IL-28B promoter affecting gene expression. PloS one. 2011; 6(10):e26620. PMID: 22046316. doi: 10.1371/journal.pone. 0026620
11. Akkarathamrongsin S, Thong VD, Payungporn S, Poovorawan K, Prapunwattana P, Poovorawan Y, et al. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6. Journal of medical virology. 2014; 86 (9):1482-90. PMID: 24782280. doi: 10.1002/jmv.23957
12. Akkarathamrongsin S, Sugiyama M, Matsuura K, Kurbanov F, Poovorawan Y, Tanaka Y, et al. High sensitivity assay using serum sample for IL28B genotyping to predict treatment response in chronic hepatitis C patients. Hepatology research: the official journal of the Japan Society of Hepatology. 2010; 40(10):956-62. PMID: 20887330. doi: 10.1111/j.1872-034X.2010.00702.x
13. Akkarathamrongsin S, Praianantathavorn K, Hacharoen N, Theamboonlers A, Tangkijvanich P, Tanaka Y, et al. Geographic distribution of hepatitis C virus genotype 6 subtypes in Thailand. Journal of medical virology. 2010; 82(2):257-62. PMID: 20029811. doi: 10.1002/jmv.21680
14. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology. 2010; 139(5):1577-85, 85 e1-3. PMID: 20708617. doi: 10.1053/j.gastro.2010. 07.058
15. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265):798-801. PMID: 19759533. doi: 10. 1038/nature08463
16. Hiramine S, Sugiyama M, Furusyo N, Uto H, Ido A, Tsubouchi H, et al. A thymine-adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus. Journal of gastroenterology. 2015. PMID: 25735432.
17. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. The New England journal of medicine. 2011; 364(25):2405-16. PMID: 21696307. doi: 10.1056/NEJMoa1012912
18. Asselah T, De Muynck S, Broet P, Masliah-Planchon J, Blanluet M, Bieche I, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. Journal of hepatology. 2012; 56(3):527-32. PMID: 21951981. doi: 10.1016/j.jhep.2011.09.008
19. Matsuura K, Watanabe T, Tanaka Y. Role of IL28B for chronic hepatitis C treatment toward personalized medicine. Journal of gastroenterology and hepatology. 2014; 29(2):241-9. PMID: 24325405. doi: 10.1111/jgh.12475
20. Aoki Y, Sugiyama M, Murata K, Yoshio S, Kurosaki M, Hashimoto S, et al. Association of serum IFNlambda with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. Journal of gastroenterology. 2014. PMID: 25501286.
21. Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke HD, et al. Interferon-lambda serum levels in hepatitis C. Journal of hepatology. 2011; 54(5):859-65. PMID: 21145813. doi: 10.1016/ j.jhep.2010.08.020
22. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol. 2008; 180(4):2474-85. PMID: 18250457.
23. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. Journal of virology. 2006; 80(9):4501-9. PMID: 16611910.
24. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nature medicine. 2006; 12(9):1023-6. Epub 2006/08/15. PMID: 16906156.
25. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. The New England journal of medicine. 2009; 361(6):580-93. PMID: 19625712. doi: 10.1056/NEJMoa0808010
26. Antaki N, Bibert S, Kebbewar K, Asaad F, Baroudi O, Alideeb S, et al. IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5. Gut. 2012; 61(11):1640-1. PMID: 22345656.
27. Seto WK, Tsang OT, Liu K, Chan JM, Wong DK, Fung J, et al. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. Journal of viral hepatitis. 2013; 20(7):470-7. PMID: 23730840. doi: 10.1111/jvh.12047